We see ImmunityBio, Inc. (IBRX) trading pre market at $9.55 USD on the NASDAQ as investors position before the company reports quarterly results on 2026-03-02. IBRX stock has posted a dramatic YTD move of +372.77% and average volume has risen to 37,880,583.00 shares. Key facts to watch in the IBRX earnings release include revenue trends, late-stage trial updates, and management guidance that could explain the gap between clinical progress and the current $9.41B market cap.

IBRX stock market snapshot and pre market flow

IBRX stock is quoted at $9.55 USD pre market on NASDAQ. The stock opened at $9.91 USD and traded between $8.98 USD and $9.97 USD in the prior session. Volume acceleration matters: 37,880,583.00 shares traded versus an average of 31,154,434.00 shares. The company’s year high is $11.00 USD and year low is $1.83 USD. These price moves set a volatile backdrop into earnings.

Earnings spotlight: what to expect in the IBRX earnings report

ImmunityBio’s earnings announcement is scheduled for 2026-03-02. Analysts and traders will parse top-line revenue, R&D cadence, and any trial-readout timing updates. Recent press shows revenue of $113.29M USD and an exceptional gross margin near 99.34% in recent periods source. We will watch management guidance for 2026 spending and cash runway assumptions. Clinical milestones can create outsized moves on earnings day.

Fundamentals and valuation for IBRX stock

The company reports EPS of -0.41 USD and a trailing PE of -23.29. Price averages show a 50-day at $4.50 USD and a 200-day at $3.02 USD, signaling a strong recent rally versus earlier ranges. Price-to-sales and EV multiples are extreme versus peers, with P/S above 80.00 and EV/Sales near 89.25. These valuation ratios reflect investor expectations for transformational pipeline value rather than current cash-flow metrics.

Technicals and trading signals for IBRX stock

Momentum indicators show strength: RSI 65.12, MACD histogram 0.23, and ADX 54.61 indicating a strong trend. Bollinger Bands sit at upper $10.72 USD, middle $7.36 USD, and lower $3.99 USD. On short timeframes, liquidity is healthy and on‑balance volume supports the rally. Traders should note ATR 1.19 USD for expected intraday movement and keep position sizes aligned to volatility.

Meyka AI rating, price targets, and model forecast

Meyka AI rates IBRX with a score of 74.34 out of 100 — Grade: B+ (BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of $2.19 USD, compared with the current $9.55 USD price, implying a model-based downside of -77.05%. Forecasts are model-based projections and not guarantees. For practical guidance we provide scenario price targets: conservative $6.00 USD, base $10.00 USD, bull $14.00 USD, tied to trial outcomes and guidance.

Risks, catalysts, and the near-term outlook for IBRX stock

Primary catalysts include the upcoming earnings release on 2026-03-02 and any clinical readouts or safety updates. Key risks are trial setbacks, cash burn, and insider activity; a recent director sale was reported source. Sector volatility in biotechnology can amplify moves. We advise watching guidance for R&D spend and milestone timelines closely.

Final Thoughts

IBRX stock trades at $9.55 USD pre market as the market braces for ImmunityBio’s earnings on 2026-03-02. The stock’s large YTD rise and elevated trading volumes reflect aggressive positioning into clinical catalysts. Fundamentals show negative EPS of -0.41 USD and stretched valuation multiples, while technicals indicate strong momentum. Meyka AI’s forecast model projects a yearly price of $2.19 USD, implying a model-based downside of -77.05% versus today. That forecast is model-based and not a guarantee. We view earnings as a binary catalyst: positive guidance or trial clarity could support the base $10.00 USD scenario, while weak guidance could push the stock toward our conservative $6.00 USD target. As an AI-powered market analysis platform, Meyka AI highlights trial milestones and cash runway as the most critical near-term drivers for investors considering IBRX stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.